Unicycive Total Revenue from 2010 to 2025

UNCY Stock  USD 0.68  0.03  4.62%   
Unicycive Therapeutics Total Revenue yearly trend continues to be fairly stable with very little volatility. Total Revenue is likely to outpace its year average in 2025. Total Revenue is the total amount of income generated by the sale of goods or services related to Unicycive Therapeutics' primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
776.2 K
Current Value
815.1 K
Quarterly Volatility
363.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.6 K, Net Interest Income of 493.9 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Total Revenue Growth Pattern

Below is the plot of the Total Revenue of Unicycive Therapeutics over the last few years. Total revenue comprises all receipts Unicycive Therapeutics generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Unicycive Therapeutics' Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Revenue10 Years Trend
Slightly volatile
   Total Revenue   
       Timeline  

Unicycive Total Revenue Regression Statistics

Arithmetic Mean201,082
Geometric Mean0.00
Coefficient Of Variation180.68
Mean Deviation301,623
Median0.00
Standard Deviation363,316
Sample Variance132B
Range951K
R-Value0.74
Mean Square Error64.4B
R-Squared0.54
Significance0
Slope56,325
Total Sum of Squares2T

Unicycive Total Revenue History

2025815.1 K
2024776.2 K
2023675 K
2022951 K

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Total Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue776.2 K815.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.